Skip to main content
Clinical Trials/EUCTR2004-000625-30-GB
EUCTR2004-000625-30-GB
Active, not recruiting
Phase 1

Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation Plus Oxygen in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator Testing - N/A

INO Therapeutics0 sites150 target enrollmentFebruary 10, 2005

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
itric Oxide for inhalation at 800ppm, plus 100% O2, to be used to assess pulmonary vaso reactivity during Pulmonary Vasodilator Testing
Sponsor
INO Therapeutics
Enrollment
150
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 10, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
INO Therapeutics

Eligibility Criteria

Inclusion Criteria

  • The patient must meet the following criteria:
  • 1\. Have any one of the three disease categories:
  • a. Idiopathic Pulmonary Arterial Hypertension
  • i. PAPm › 25mmHg at rest, PCWP \= 15mmHg, and PVRI › 3 u· m2 or diagnosed clinically with no previous catheterization.
  • b. CHD with pulmonary hypertension repaired and unrepaired,
  • i. PAPm › 25mmHg at rest, and PVRI › 3 u· m2 or diagnosed clinically with no previous catheterization
  • c. Cardiomyopathy
  • i. PAPm › 25mmHg at rest, and PVRI › 3 u•m2 or diagnosed clinically with no previous catheterization.
  • 2\. Scheduled to undergo right heart catheterization to assess pulmonary vasoreactivity by acute pulmonary vasodilation testing.
  • 3\. Males or females, ages 4 weeks to 18 years, inclusive

Exclusion Criteria

  • The patient will be excluded from enrolment if any of the following are true:
  • 1\. Focal pulmonary infiltrates on chest radiograph.
  • 2\. Diagnosed with severe obstructive or restrictive pulmonary disease that is significantly contributing to the patient’s pulmonary hypertension.
  • 3\. Received treatment with nitric oxide for inhalation within 30 days prior to study initiation, or are on other investigational medications, nitroglycerin, sodium nitroprusside, sildenafil, other PDE\-5 inhibitors, or prostacyclin.
  • 4\. Pregnant (urine HCG \+).
  • 5\. Baseline PCWP \> 20 mmHG.

Outcomes

Primary Outcomes

Not specified

Similar Trials